- Home
- / Voyager Therapeutics
Voyager Therapeutics
Stock Price
$8.9
2023-09-11
Market Capitalization
$390.7 M
2023-09-11
Revenue
$40.9 M
FY, 2022
Voyager Therapeutics Summary
Company Summary
- Overview
- Voyager Therapeutics is a gene therapy company developing treatments for diseases of the central nervous system (CNS). It offers therapies for such diseases as Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis, and Friedreich’s ataxia.
- Type
- Public
- Status
- Active
- Founded
- 2014
- HQ
- Cambridge, MA, US | view all locations
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Allen Nunnally, Chief Business Officer
Robin Swartz, Chief Operating Officer
Michelle Quinn Smith, Chief Human Resources Officer
Operating MetricsView all
Patent Applications
351
4.6%
FY, 2021
Patents Issued
229
15.1%
FY, 2021
Voyager Therapeutics Financials
Summary Financials
- Revenue (Q2, 2023)
- $4.9M
- Net income (Q2, 2023)
- ($22.2M)
- Cash (Q2, 2023)
- $244.3M
- EBIT (Q2, 2023)
- ($25.4M)
- Enterprise value
- $168.2M